Given its role in cancer, SHP2 is considered a promising target for therapeutic intervention. Several [small molecule inhibitors]() of SHP2 are currently being developed and tested in clinical trials. These inhibitors aim to block the phosphatase activity of SHP2, thereby disrupting aberrant signaling pathways that drive cancer progression.